- Home
- OLP vs KROS Comparison
OLP vs KROS Comparison
Compare OLP & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLP
- KROS
- Stock Information
- Founded
- OLP 1982
- KROS 2015
- Country
- OLP United States
- KROS United States
- Employees
- OLP N/A
- KROS N/A
- Industry
- OLP Real Estate Investment Trusts
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- OLP Real Estate
- KROS Health Care
- Exchange
- OLP Nasdaq
- KROS Nasdaq
- Market Cap
- OLP N/A
- KROS 589.8M
- IPO Year
- OLP N/A
- KROS 2020
- Fundamental
- Price
- OLP $25.52
- KROS $11.84
- Analyst Decision
- OLP Strong Buy
- KROS Buy
- Analyst Count
- OLP 1
- KROS 11
- Target Price
- OLP $28.00
- KROS $45.33
- AVG Volume (30 Days)
- OLP 51.6K
- KROS 2.1M
- Earning Date
- OLP 03-04-2025
- KROS 02-26-2025
- Dividend Yield
- OLP 7.05%
- KROS N/A
- EPS Growth
- OLP 51.11
- KROS N/A
- EPS
- OLP 1.63
- KROS N/A
- Revenue
- OLP $89,142,000.00
- KROS $651,000.00
- Revenue This Year
- OLP N/A
- KROS $303.27
- Revenue Next Year
- OLP $4.71
- KROS N/A
- P/E Ratio
- OLP $15.66
- KROS N/A
- Revenue Growth
- OLP N/A
- KROS 8037.50
- 52 Week Low
- OLP $19.25
- KROS $9.78
- 52 Week High
- OLP $30.45
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- OLP 37.95
- KROS 24.87
- Support Level
- OLP $25.08
- KROS $10.95
- Resistance Level
- OLP $26.25
- KROS $11.63
- Average True Range (ATR)
- OLP 0.58
- KROS 0.87
- MACD
- OLP 0.02
- KROS 1.31
- Stochastic Oscillator
- OLP 27.89
- KROS 30.60
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.